OR WAIT 15 SECS
Omya will showcase Omyapharm 500-OG (calcium carbonate and tribasic calcium phosphate) at CPhI Worldwide in Madrid, Spain, on Oct. 9–11, 2018.
Mineral producer Omya will showcase its excipient, Omyapharm 500-OG (calcium carbonate and tribasic calcium phosphate) at CPhI Worldwide to be held in Madrid, Spain, on Oct. 9–11, 2018. The highly porous inactive ingredient provides compactability, good mechanical stability, high absorption capacity, and rapid disintegration to facilitate the production of tablets and granules.
The company will demonstrate the multiple benefits of the excipient at its booth, H101, in Hall 8. The company’s team of pharma experts will be available to answer technical questions and discuss further possible applications. The company has an in-house laboratory for solid dosage forms and is able to provide specific formulation services, including creating innovative mineral solutions for pharmaceuticals and supporting the development of optimal applications.
According to the company, case studies have shown that Omyapharm 500-OG is a good filler-binder for tablets in dry granulation processes. It combines good compactability with a fast disintegration time due to its porosity and specific surface properties. This results in harder tablets at low compression forces. In addition, the excipient can be used as an efficient carrier for converting oils and liquids into compressible powders.
In a recent study, scientists also confirmed the ability of Omyapharm to formulate orally disintegrating tablets (ODTs) with enhanced mouthfeel, the company reports. The tablets were well accepted and-in correlation with an in vitro model-disintegrated quickly in vivo. The study suggests that the excipient can be successfully used in ODTs without causing unpleasant sensations in the mouth.
CPhI Worldwide runs from Oct. 9–11, 2018 in Madrid, Spain.